Amgen spent most of the 2010s as the quiet giant of biotech, printing cash from a handful of blockbuster drugs and returning nearly all of it to shareholders. Then, in October 2023, it paid $27.8 billion for Horizon Therapeutics, the largest acquisition in its history, and transformed itself overnight from a mature cash machine into something more complicated: a growth story carrying a mountain of debt, racing to build new revenue before its old drugs lose legal protection. Today, the stock sits near an all-time high. The filed numbers tell a more ambiguous story.
The short version
Amgen’s revenue is growing again, and the operating engine is genuinely strong. But the stock’s price-to-sales ratio sits at the 99th percentile of its own decade, meaning the market is paying more for each dollar of Amgen’s sales than at almost any point in the last ten years. Meanwhile, five drugs accounting for roughly four in every ten dollars of 2025 revenue face patent expiration by 2029. Those two facts cannot both be comfortable at the same time, and the gap between them is the story.
A business in transition, priced for arrival
The math here, meaning what the filed fundamentals actually justify, and the mood, meaning what investors are currently willing to pay, have rarely been further apart for this company. Amgen’s 10-K for fiscal year 2025 shows total revenues of $36.8 billion, up 10% from the prior year, with a GAAP operating margin that reflects a genuinely healthy core business. The Horizon acquisition, which closed in late 2023, added rare-disease drugs that together generated nearly $4 billion in 2025 sales, making the deal look, so far, like it earned its price.
But look at what the mood is paying for all that. At recent prices, our data puts Amgen’s price-to-sales ratio at the 99th percentile of its own decade-long range. A ratio like this is simply the price tag per dollar of revenue: investors are paying more for each dollar Amgen earns than at virtually any moment in the past ten years. The P/E ratio, the price per dollar of annual profit, sits meaningfully above its ten-year median. That gap is the mood asking the math to deliver something it hasn’t yet proven it can.
The cliff the revenue chart doesn’t show
Here is the tension hiding inside the growth story. Five drugs, including Enbrel, Prolia, Xgeva, Otezla, and Repatha, together accounted for roughly 38% of Amgen’s 2025 revenue. All five face U.S. patent expiration by 2029, meaning generic and biosimilar competitors can legally undercut their prices. This isn’t a distant risk. Enbrel sales fell sharply in 2025, and the Q1 2026 10-Q shows Prolia and Xgeva combined revenue down nearly a third year-over-year in that quarter alone. A business losing four in every ten revenue dollars to patent expiry over the next three years needs its replacement drugs to run very fast just to stay in place.
The debt picture adds weight to that math. The Q2 2026 10-Q shows total debt of $57.3 billion as of June 30, 2026, a sum accumulated largely through the Horizon acquisition. To put that in kitchen-table terms: imagine a household earning $40,000 a year carrying more than $60,000 on a credit card. The interest alone consumes a meaningful share of every paycheck before a single bill gets paid. Amgen’s cash position, filed in the 2025 10-K, provides a cushion, but the company suspended share buybacks entirely through the first half of 2026, a signal that capital is being husbanded carefully.
Where the growth is actually coming from
The bull case is real, and it deserves a fair hearing. Q2 2026 results show revenues up 10% from the same quarter a year earlier, with free cash flow of $3.5 billion in a single quarter. That free cash flow figure, what’s left after the company pays to keep itself running and invest in its future, is a substantial sum relative to what the Horizon acquisition costs in annual interest. The operating engine, stripped of accounting noise, is producing real money.
The pipeline is also moving. IMDELLTRA, Amgen’s lung cancer drug, received full FDA approval for small cell lung cancer this year, and data presented October 24, 2026, showed that combining it with AstraZeneca’s Imfinzi cut the risk of death by 58% in first-line maintenance treatment, a result that could substantially expand its addressable market. LUMAKRAS won a new colorectal cancer approval. TEZSPIRE added a nasal polyp indication. These are not minor label extensions.
Then there is MariTide, Amgen’s obesity drug, now in Phase 3 trials. The obesity market is large enough that a single successful drug could reshape the company’s revenue profile for a decade. Management is already spending to build manufacturing capacity ahead of a potential launch, which is a confident posture, though it also means costs are rising before revenues arrive. The Q3 2026 earnings call, scheduled for November 3, will be the first chance to hear management characterize how that spending is tracking.
What the analysts are arguing about
The sell-side is split in a way that reflects the underlying uncertainty honestly. Oppenheimer cited pipeline momentum in raising its valuation estimate in late October 2026; RBC Capital also moved its target higher in early October. By contrast, the consensus of dozens of analysts polled by S&P Global, as reported by Stock Analysis, reflects an average target below recent trading levels, and BMO Capital maintained a neutral stance in mid-October. GuruFocus’s GF Value model, which applies its own proprietary methodology, placed the stock in an overvalued range relative to that estimate as of the dates reviewed, one data point among several that analysts are weighing differently. The disagreement illustrates how differently analysts are weighting pipeline potential against valuation risk, not a signal of what any reader should do. The disagreement is not about whether Amgen is a good business. It is about whether the current price already assumes the best-case outcome.
Reading the numbers
- P/S ratio at the 99th percentile of its own decade (our data). The price-to-sales ratio is simply the price tag per dollar of annual revenue. Amgen’s current ratio of 5.87 means investors are paying $5.87 for every $1 of sales, more than at 99% of moments in the past ten years. A household analogy: if a neighbor’s house sold for more than it has at any point in a decade, the natural question is what justifies the premium, the same question the valuation data raises here.
- $57.3 billion in total debt, as shown in the Q2 2026 10-Q. This is the sum Amgen owes to bondholders, accumulated largely through the Horizon acquisition. It is more than 1.5 times what the entire company earns in revenue in a year. Debt at this scale means a significant share of every operating dollar goes to interest before shareholders see anything.
- $14 billion in revenue at patent risk by 2029 (2025 10-K). Five drugs generating roughly 38% of 2025 revenue face biosimilar competition within three years. If a business earned $100,000 a year and knew $38,000 of it was disappearing by 2029, it would need to find that money somewhere else. That is the replacement problem Amgen’s pipeline must solve.
- $3.5 billion in free cash flow in Q2 2026 alone. Free cash flow is what’s left after paying operating costs and capital investment, the money available to pay debt, dividends, or fund new drugs. A single quarter producing this much cash confirms the core business is healthy. The question is whether it stays healthy as older drugs fade.
For the standing yardsticks on Amgen: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Amgen.
Sources
- Amgen 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Amgen 10-Q, quarter ended March 31, 2026 (SEC EDGAR)
- Amgen 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Amgen Q2 2026 earnings press release
- IMDELLTRA Phase 3 DeLLphi-305 data, ESMO 2026 (Seeking Alpha)
- Oppenheimer valuation estimate raise, October 23, 2026 (Investing.com)
- Analyst consensus and price targets (Stock Analysis)
- Amgen completes Horizon Therapeutics acquisition, October 2023
